A phase III trial in untreated advanced RCC (CheckMate 9ER) demonstrated nivolumab (anti‐PD1) plus cabozantinib (anti‐VEGFR) was safe and effective with a median PFS of 16.6 months and 85.7% overall survival (OS) at 12 months compared to PFS of 8.3 months and OS at 12 months of 75.6% for sunitinib.35 Here, KDR is linked to renal cell adenocarcinoma.